Literature DB >> 11581617

Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.

Y Ichinose1, H Kato, T Koike, R Tsuchiya, T Fujisawa, N Shimizu, Y Watanabe, T Mitsudomi, M Yoshimura, M Tsuboi.   

Abstract

BACKGROUND: The number of N2 stations (single vs multiple N2 stations) is an important prognostic factor in patients with completely resected stage IIIA-N2 non-small cell lung cancer. However, the significance of both the N2 station(s) actually involved and the primary tumor location remains unclear.
METHODS: The database was built with the use of a questionnaire survey on the survival of patients with pathologic stage IIIA-N2 non-small cell lung cancer completely resected between January 1992 and December 1993. The survey was performed by the Japan Clinical Oncology Group as of July 1999. The data include information on the survival and N2 stations of 402 patients.
RESULTS: A frequently metastasized single N2 station was the lower pretracheal station in primary tumors in the right upper lobe, the subaortic station in the left upper lobe, and the subcarinal station in the right middle or lower lobe and the left lower lobe. In multiple N2 stations, the frequency of metastasis of the N2 station observed in a single N2 station was as high as 72% to 89%, and one or two other frequently metastasized stations were added to each group. Regarding the survival of patients with a primary tumor in each lobe except for the left lower lobe, a single N2 station resulted in a significantly better survival than did multiple N2 stations. Furthermore, the overall survivals classified according to each primary site showed a significant difference among the four primary sites (P =.04).
CONCLUSIONS: The primary tumors in each lobe showed a prevalence of N2 station(s). The number of N2 stations is a good prognosticator except in patients with a primary tumor in the left lower lobe. In addition, the site of a primary tumor itself is also considered to influence the survival of the patients.

Entities:  

Mesh:

Year:  2001        PMID: 11581617     DOI: 10.1067/mtc.2001.116473

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  29 in total

1.  Pleomorphic carcinoma of the lung with mediastinal extension following malignant lymphoma: report of a case.

Authors:  Takahiro Nakajima; Toshihiko Iizasa; Akira Iyoda; Kenzo Hiroshima; Kazuhiro Yasufuku; Masako Chiyo; Takashi Anayama; Hidemi Suzuki; Kiyoshi Shibuya; Hidemi Ohwada; Takehiko Fujisawa
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer.

Authors:  Koji Takahashi; William Stanford; Edwin Van Beek; Brad Thompson; Brian Mullan; Yutaka Sato
Journal:  Radiat Med       Date:  2007-10-26

3.  Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.

Authors:  Keishi Kawasaki; Yasunori Sato; Yoshio Suzuki; Haruhisa Saito; Yukihiro Nomura; Yukihiro Yoshida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-01-26       Impact factor: 1.520

4.  Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes.

Authors:  Haruhisa Matsuguma; Izumi Oki; Rie Nakahara; Norihisa Ohata; Seiji Igarashi; Kiyoshi Mori; Shunsuke Endo; Kohei Yokoi
Journal:  Eur J Cardiothorac Surg       Date:  2012-01       Impact factor: 4.191

5.  Is tumor location an independent prognostic factor in locally advanced non-small cell lung cancer treated with trimodality therapy?

Authors:  Kazuhiko Shien; Shinichi Toyooka; Junichi Soh; Hiromasa Yamamoto; Shinichiro Miyoshi
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

6.  We should be done in such a way that patients with stage IV non-small cell lung cancer who would benefit from surgery are not overlooked.

Authors:  Yasuhiro Chikaishi; Ayako Hirai; Naoko Imanishi; Yoshinobu Ichiki; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

7.  Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?

Authors:  Yasunobu Funakoshi; Yukiyasu Takeuchi; Hidenori Kusumoto; Toru Kimura; Hajime Maeda
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

8.  Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.

Authors:  Chi-Fu Jeffrey Yang; Syed M Adil; Kevin L Anderson; Robert Ryan Meyerhoff; Ryan S Turley; Matthew G Hartwig; David H Harpole; Betty C Tong; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  Eur J Cardiothorac Surg       Date:  2015-12-30       Impact factor: 4.191

9.  Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy.

Authors:  Kazuhiko Shien; Shinichi Toyooka; Junichi Soh; Katsuyuki Hotta; Kuniaki Katsui; Takahiro Oto; Susumu Kanazawa; Katsuyuki Kiura; Hiroshi Date; Shinichiro Miyoshi
Journal:  Mol Clin Oncol       Date:  2015-02-11

Review 10.  [Indications and limitations of fresh frozen sections in the pulmonary apparatus].

Authors:  K Pütz; M Engels; C Vollbrecht; L C Heukamp; A C Adam; R Büttner
Journal:  Pathologe       Date:  2012-09       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.